US Generic Pharma, Drug Distributors and Life Sciences Risk – A Moody’s Conversation: BI Replay

Generic-to-specialty, cost cutting and M&A are strategies that generic drug manufacturers, distributors and life sciences companies have used to reduce earnings pressure as they face multiple headwinds ranging from input cost inflation to regulatory pressure and tariffs. Please join Bloomberg Intelligence Senior Credit Analyst Jean-Yves Coupin and Moody’s analysts Vladimir Ronin and David Locker for a discussion on credit themes to consider for the rest of the year, including risk mitigation strategies, legislative and regulatory risks, and outlook for credit ratings.